Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on OKMETIC OYJ. We currently have 0 research reports from 0 professional analysts.
|08Nov16 13:45||GNW||NSIG Finland S.à r.l. has gained title to all the shares in Okmetic Oyj and the shares will delist from Nasdaq Helsinki|
|04Nov16 11:30||GNW||The arbitral tribunal has confirmed NSIG Finland S.À R.L.'S redemption right regarding the shares in Okmetic Oyj and public trading in the company's shares has been terminated|
|22Sep16 10:11||GNW||The listing committee of Nasdaq Helsinki has resolved to delist the shares of Okmetic Oyj|
|15Sep16 07:45||GNW||Change in Okmetic's financial reporting|
|15Sep16 07:31||GNW||Okmetic Oyj applies for delisting of its shares from the official list of Nasdaq Helsinki|
|31Aug16 08:00||GNW||Arbitrator appointed for the redemption proceedings concerning Okmetic's minority shares|
|22Jul16 06:00||GNW||Okmetic Oyj interim report 1 January - 30 June 2016: Strong cash flow in very challenging market situation|
Frequency of research reports
Research reports on
Recovery not reflected in the share price
25 Apr 17
Prelims for the year to January 2017 are in-line but more importantly they confirm the restructuring process is now complete, prove the commerciality of its cloud based platform and demonstrate a move towards higher margin services. PBT was £1.2m (against a loss last year), adjusted EBITDA grew 56% to £2m and cash from operations turned positive at £0.9m allowing a net cash position to be maintained. For this year, we expect PBT growth of 77% to £2.2m (previously £2.5m), implying a current PE rating of 15x. We reiterate our buy recommendation with a 2.2p price target as the turn around generated by Redstone has yet to be reflected in the share price.
Panmure Morning Note 25-04-2017
25 Apr 17
Blancco Technology, a leading provider of data erasure solutions and mobile device diagnostics, has issued a mixed Q3 trading update. On the positive side, revenue progression has been extremely strong, with a material acceleration in sales growth during the quarter: +48% CFX basis during 3Q17 vs +28% during 1H17. However, cash flow is weaker than expected and management has guided that year end net debt is expected to be £5.5m (previously we were looking for net debt of £3.6m). Due to the timing of cash flows management has identified the need for additional short term funding of £4m over the coming weeks.
N+1 Singer - Servelec Group - Calling the bottom
20 Apr 17
We are increasingly confident that Servelec’s travails are behind it and the business is returning to growth. Recent share price weakness looks unwarranted in this context and the valuation now looks compelling. Our forecasts are essentially unchanged, but we see medium term upside as the group’s markets improve. Servelec remains a key idea for 2017 and we reiterate our Buy recommendation and 325p Target Price.
N+1 Singer - Small-cap quantitative research - Growth style screen revamp and 10 focus stocks
06 Apr 17
We have reviewed the performance of our consistent growth screen since the previous refresh on 27 September 2016 and revamped the selection parameters to focus more on forecast sales and EPS growth going forward. In the period under review the consistent growth style screen outperformed the small-cap benchmark by c. 6% and underperformed the microcap index by a similar amount. Interestingly, although growth doesn’t always seem to be defensive as might be expected, however it appears right to buy growth on dips caused by or coincident with wider market volatility. In the new forecast growth screen we take a close look at 10 focus stocks. We will monitor performance and refresh it in three to four months time.
Pickup in H2 organic growth as expected
20 Apr 17
Headline revenue growth of 19% reflects a full half contribution of ID Scan and a pickup in organic growth to 12% across the year driven by the excellent performance from the higher margin international services. The mix effects of this growth resulted in EBIT of £17m, 4% ahead of our forecasts, and a 1.1pp improvement in the operating margin.